11 completed, 3 active not recruiting, 1 terminated. 15 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 15 | Completed 11, Active not recruiting 3, Terminated 1 |
| Phase 2 | 4 | Active not recruiting 2, Completed 2 |
Follow erdafitinib: new trials by email Literature Review of erdafitinib trials Research Report on erdafitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer Erdafitinib Intravesical Delivery System - Urinary Bladder Neoplasms, Receptors, Fibroblast Growth Factor | Phase 1 | Completed | Janssen Pharmaceutical K.K. | 5 | 2023-03-03 | 2026-11-03 |
| Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy Biospecimen Collection, Bone Scan, Computed Tomography - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2022-07-07 | 2026-11-20 |
| Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer Erdafitinib Intravesical Delivery System - Non-Muscle Invasive Bladder Neoplasms | Phase 1 / Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 235 | 2022-04-11 | 2026-11-03 |
| A Study of Steady-state Carbamazepine on the Single-dose of Erdafitinib Tablets in Healthy Adult Participants Erdafitinib, Carbamazepine - Healthy | Phase 1 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 15 | 2020-03-31 | 2023-06-29 |
| Myeloma-Developing Regimens Using Genomics (MyDRUG) Abemaciclib, dexamethasone, ixazomib, pomalidomide, Enasidenib, dexamethasone, ixazomib, pomalidomide, Cobimetinib, dexamethasone, ixazomib, pomalidomide - Relapsed Refractory Multiple Myeloma | Phase 1 / Phase 2 | Completed | Multiple Myeloma Research Consortium | 103 | 2019-04-01 | 2025-02-14 |
| A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib Erdafitinib - Hepatic Impairment | Phase 1 | Terminated | Janssen Research & Development, LLC | 26 | 2018-12-06 | 2025-02-03 |
| A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers JNJ-63723283, Erdafitinib - Neoplasm | Phase 1 | Completed | Janssen Pharmaceutical K.K. | 22 | 2018-08-31 | 2025-04-28 |
| A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer Erdafitinib, Cetrelimab, Cisplatin - Urothelial Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 125 | 2018-04-05 | 2026-08-28 |
| Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer Erdafitinib, Palbociclib, Fulvestrant - Metastatic Breast Cancer | Phase 1 | Completed | Vanderbilt-Ingram Cancer Center | 35 | 2017-08-18 | 2024-11-14 |
| A Study to Evaluate the Effect of Fluconazole and Itraconazole on Erdafitinib Pharmacokinetics in Healthy Adult Participants Erdafitinib, Fluconazole, Itraconazole - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 54 | 2017-04-14 | 2025-02-03 |
| A Study to Determine the Effect of Food on the Pharmacokinetics of Erdafitinib in Healthy Participants Erdafitinib - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 16 | 2017-03-14 | 2017-06-23 |
| A Study to Assess the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ--42756493 to Healthy Male Participants JNJ-42756493 - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 8 | 2016-03-01 | 2017-10-23 |
| Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma JNJ-42756493 (erdafitinib) - Carcinoma, Hepatocellular | Phase 1 / Phase 2 | Completed | Janssen Research & Development, LLC | 53 | 2015-05-25 | 2025-02-03 |
| Pharmacokinetic Study of JNJ-42756493 in Healthy Participants JNJ-42756493 10 mg tablet, JNJ-42756493 10 mg Oral Solution, JNJ-61818549 - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 8 | 2014-10-01 | 2015-01-08 |
| Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Tablet Versus JNJ-42756493 Capsule in Healthy Participants JNJ-42756493 Tablet, JNJ-42756493 Capsule, JNJ-61818549 - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 12 | 2014-09-01 | 2014-12-03 |
Carcinoma, Transitional Cell (2) · Urinary Bladder Neoplasms (2) · Acrocephalosyndactylia (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Multiple Myeloma (1) · Neoplasms (1) · Non-Muscle Invasive Bladder Neoplasms (1) · Ureteral Neoplasms (1) · Urethral Neoplasms (1)
Janssen Research & Development, LLC (9) · Janssen Pharmaceutical K.K. (2) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1) · Multiple Myeloma Research Consortium (1) · National Cancer Institute (NCI) (1) · Vanderbilt-Ingram Cancer Center (1)
United States (7) · Belgium (5) · Japan (3) · South Korea (3) · Canada (2) · Germany (2) · Spain (2) · Taiwan (2) · Belarus (1) · Brazil (1) · China (1) · France (1) · Israel (1) · Italy (1) · Netherlands (1)
Brent Rexer, MD, PhD (1) · Hearn J Cho, M.D., Ph.D. (1) · Rohit Jain (1)
PMID 31673875, PMID 39971605, PMID 40627530, PMID 41538748
2014 (2), 2017 (2), 2023 (2), 2018 (1), 2019 (1), UM1CA186644 (1)